Drugs / 2-Deoxy-2-[18F] fluoro-D-glucose (FDG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05015881 Background | Nov 2021 → Dec 2026 expected | alcohol-related disorders | University of Pennsylvania | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) | “2-Deoxy-2-[18F] fluoro-D-glucose (FDG)” NCT05015881 ↗ |
| Known as | FDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05015881 ↗ |
| Modality | Diagnostic / imaging agent | “Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.” NCT05015881 ↗ |
| Route | Intravenous | “The FDG tracer will be injected using the IV after positioning on the scanner.” NCT05015881 ↗ |